TriMaximize: A Multicentre, Prospective, Non-interventional Trial Monitoring Therapy Pathways of Asthma Patients Treated With an Extra-fine ICS/LABA/LAMA Single-inhaler Triple Therapy in a Real-world Setting and Characterizing the Effects on Health-related Outcomes.
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
TriMaximize: A multicentre, prospective, non-interventional trial monitoring therapy pathways of asthma patients treated with an extra-fine ICS/LABA/LAMA single-inhaler triple therapy in a real-world setting and characterizing the effects on health-related outcomes.
Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:
• Patients ≥ 18 years of age,
• Patients with confirmed leading diagnosis of asthma with or without concomitant COPD,
• Physician decision to start fixed triple therapy with ICS/LABA/LAMA (Trimbow® MS or HS) according to its current authorised indication. The treatment decision must be made independently from participation in this NIS,
• Patients willing and able to sign an informed consent for use of their pseudonymised clinical data within the present non-interventional study.
Locations
Other Locations
Poland
Indywidualna Specjalistyczna Praktyka Lekarska
RECRUITING
Tarnowskie Góry
Contact Information
Primary
Tomasz Debowski, Md Phd
t.debowski@chiesi.com
+48-800 506 122 982
Backup
Maciej Wojakiewicz, Phd
m.wojakiewicz@chiesi.com
+48-800 697 400 054
Time Frame
Start Date: 2024-08
Estimated Completion Date: 2025-08-01
Participants
Target number of participants: 60
Related Therapeutic Areas
Sponsors
Leads: Chiesi Poland Sp. z o.o.
Collaborators: Gesellschaft für Therapieforschung mbH